• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Gains 100 Points; Biomerica Shares Spike Higher

    12/18/23 2:21:38 PM ET
    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRA alert in real time by email

    U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday.

    The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07. The S&P 500 also rose, gaining, 0.54% to 4,744.58.

    Check This Out: Snap To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday

     

    Leading and Lagging Sectors

     

    Communication services shares rose by 2.1% on Monday.

    In trading on Monday, real estate shares fell by 0.3%.

     

    Top Headline

     

    ZimVie Inc. (NASDAQ:ZIMV) disclosed an agreement to sell its spine business to H.I.G. Capital for $375 million.

     

    Equities Trading UP

     

    Invivyd, Inc. (NASDAQ:IVVD) shares shot up 147% to $4.03 after the company announced initial results from its CANOPY Phase 3 trial of VYD222.

    Shares of Biomerica, Inc. (NASDAQ:BMRA) got a boost, surging 60% to $1.58. Biomerica received FDA 510(k) clearance for its Hp Detect Stool Antigen ELISA test, designed to detect the presence of the H. pylori bacteria.

    ZimVie Inc. (NASDAQ:ZIMV) shares were also up, gaining 43% to $16.02 after the company disclosed an agreement to sell its spine business to H.I.G. Capital for $375 million.

     

    Equities Trading DOWN

     

    Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) shares dropped 44% to $1.8574. The FDA has issued a Complete Response letter to Checkpoint Therapeutics' Cosibelimab Biologic License Application for metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

    Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) were down 39% to $36.13 after the company announced a comprehensive development program update for GSBR-1290.

    Ebix, Inc. (NASDAQ:EBIX) was down, falling 65% to $1.7150 after the company and certain US affiliates filed for protection under Chapter 11 and reached a stalking horse agreement to sell its North American Life and Annuity assets to Zinnia.

    Also Check This Out: How To Earn $500 A Month From Darden Restaurants Stock Following Upbeat Earnings

     

    Commodities

     

    In commodity news, oil traded up 0.9% to $72.10 while gold traded up 0.2% at $2,040.30.

    Silver traded down 0.1% to $24.14 on Monday while copper fell 1.1% to $3.8475.

     

    Euro zone

     

    European shares closed mostly lower today. The eurozone’s STOXX 600 slipped 0.27%, London’s FTSE 100 gained 0.50% while Spain’s IBEX 35 Index fell 0.40% The German DAX fell 0.60% French CAC 40 fell 0.37%, while Italy’s FTSE MIB Index fell 0.44%.

    The Ifo Business Climate indicator for Germany fell to a three-month low level of 86.4 in December versus a revised reading of 87.2 in November.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Monday, with Japan’s Nikkei 225 falling 0.64%, Hong Kong’s Hang Seng Index declining 0.97% and China’s Shanghai Composite Index falling 0.40%. India’s S&P BSE Sensex, meanwhile, fell 0.24%.

    Singapore's non-oil domestic exports rose by 1% year-over-year in November compared to a revised 3.5% decline in October.

     

    Economics

     

    The NAHB/Wells Fargo Housing Market Index in the U.S. rose to 37 in December from 34 in the prior month, and topping market estimates of 36.

    Now Read This: Top 3 Health Care Stocks That Are Preparing To Pump This Month

    Get the next $BMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRA
    $CKPT
    $EBIX
    $GPCR

    CompanyDatePrice TargetRatingAnalyst
    Invivyd Inc.
    $IVVD
    12/22/2025$10.00Buy
    BTIG Research
    Invivyd Inc.
    $IVVD
    11/25/2025Buy → Hold
    D. Boral Capital
    Invivyd Inc.
    $IVVD
    10/6/2025$10.00Overweight
    Cantor Fitzgerald
    ZimVie Inc.
    $ZIMV
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    ZimVie Inc.
    $ZIMV
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    Structure Therapeutics Inc.
    $GPCR
    5/2/2025$60.00Buy
    Citigroup
    ZimVie Inc.
    $ZIMV
    4/10/2025$16.00Buy
    B. Riley Securities
    ZimVie Inc.
    $ZIMV
    3/13/2025Buy → Hold
    Needham
    More analyst ratings

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

    LIBERTY is part of the Company's broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable AmericansThe LIBERTY clinical trial will evaluate comparative safety and immunology of VYD2311 versus mRNA COVID vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID vaccineFDA, providing feedback jointly from CDER and CBER, requested specific monitoring of adverse events of special interest (AESIs) relevant to mRNA COVID vaccines, citing the known risk of myocarditis/pericarditis in the young adult population following mRNA COVID vaccination;

    2/3/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

    The educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will advance public understanding of antibodies as a centerpiece of modern wellness strategiesMedia campaign planned to launch in spring 2026 following Ms. Vonn's closely watched and inspiring comeback season NEW HAVEN, Conn., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced a partnership with renowned ski champion Lindsey Vonn to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in preventing disease. A national multimedia education campaign is planned to launch i

    1/22/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

    Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike proteinDesign includes multiple highly active antibody doses administered over the long term to assess the safety and potential clinical benefit of VYD2311 treatment, versus placeboMillions of individuals continue to live with persistent and debilitating symptoms of Long COVID, unde

    1/20/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Invivyd Inc.

    SCHEDULE 13G/A - Invivyd, Inc. (0001832038) (Subject)

    2/13/26 4:10:03 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

    SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    2/13/26 8:46:14 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

    SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    2/10/26 11:23:20 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Invivyd with a new price target

    BTIG Research initiated coverage of Invivyd with a rating of Buy and set a new price target of $10.00

    12/22/25 8:39:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd downgraded by D. Boral Capital

    D. Boral Capital downgraded Invivyd from Buy to Hold

    11/25/25 8:11:06 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Invivyd with a new price target

    Cantor Fitzgerald initiated coverage of Invivyd with a rating of Overweight and set a new price target of $10.00

    10/6/25 8:27:43 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Duke William E.

    4 - Invivyd, Inc. (0001832038) (Issuer)

    1/30/26 4:20:47 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Human Resources Officer Green Julie

    4 - Invivyd, Inc. (0001832038) (Issuer)

    1/30/26 4:20:06 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Lee Timothy Edward

    4 - Invivyd, Inc. (0001832038) (Issuer)

    1/30/26 4:16:38 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Checkpoint Therapeutics Inc.

    SC 13G/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    11/14/24 4:49:25 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

    Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Diagnostics, one of the world's largest clinical laboratories. Mr. Huff is a hands-on, inspirational,

    10/8/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

    Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

    12/8/25 8:00:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

    SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

    12/7/25 6:20:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

    NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company's investor relations website shortly after the event. About Invivyd Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical c

    11/3/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $CKPT
    $EBIX
    $GPCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hebard George bought $376,280 worth of shares (409,000 units at $0.92), increasing direct ownership by 998% to 450,000 units (SEC Form 4)

    4 - EBIX INC (0000814549) (Issuer)

    1/3/24 11:28:13 AM ET
    $EBIX
    EDP Services
    Technology